Joshua Allan Garcia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joshua Allan Garcia has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aaron G. Matlock
Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, USA
1 shared publication - Bhanu Sud
Providence St. Jude Medical Center, 101 E Valencia Mesa Dr., Fullerton, CA 92835, USA
1 shared publication - Brit Long
Department of Emergency Medicine, Mayo Clinic College of Medicine, Rochester, MN
1 shared publication Garcia
1 shared publication- Giovani Leon
College of Pharmacy, Marshall B. Ketchum University, 2575 Yorba Linda Blvd., Fullerton, CA 92831, USA
1 shared publication - Kayvan Moussavi
Department of Pharmacy Practice, College of Pharmacy, Marshall B. Ketchum University, Fullerton, California; Clinical Education, Providence St. Joseph Hospital Orange, Orange, California
1 shared publication
Latest Publications
- 3 March 2025
- Published by Wolters Kluwer Health in Journal of Infusion Nursing
- Vol. 48 (2) , 123-126
Antimicrobial Therapy for Pseudomonas aeruginosa
- 3 March 2025
- Published by Wolters Kluwer Health in Journal of Infusion Nursing
- Vol. 48 (2) , 123-126
Antimicrobial Therapy for Pseudomonas aeruginosa
- Open Access
- 29 September 2024
- Published by MDPI AG in Pharmacoepidemiology
- Vol. 3 (4) , 307-313
Off-Label Use of Dalbavancin in Enterococcus spp. Abscess and Streptococcus pneumoniae Bacteremia Secondary to Septic Arthritis: A Retrospective Case Report
Dalbavancin, a semi-synthetic lipoglycopeptide with an extended half-life that allows for weekly dosing, is currently approved for the treatment of bacterial skin and soft tissue infections caused by susceptible gram-positive organisms. This case report discusses the successful treatment of septic arthritis with dalbavancin in a 38-year-old obese male. Septic arthritis, commonly caused by Staphylococcus aureus and Streptococcus species, was diagnosed in this patient following a mechanical fall that led to worsening shoulder pain. Given the patient’s morbid obesity and concerns about antibiotic penetration, dalbavancin 1500 mg IV biweekly was chosen for its extended half-life and ease of administration. This case underscores dalbavancin’s efficacy in managing septic arthritis in obese patients, offering a convenient alternative to traditional therapies that require a peripherally inserted central catheter (PICC line), frequent dosing, therapeutic monitoring, and prolonged hospital stays. Despite its higher cost, dalbavancin’s advantages include reduced need for PICC lines, additional staff and resources to monitor therapeutic drug levels, and fewer complications, which can offset some expenses. To our knowledge, this is the first documented case investigating the use of dalbavancin for enterococcal septic arthritis with a biweekly dosing regimen.
- 29 September 2024
- Published by MDPI AG in Pharmacoepidemiology
- Vol. 3 (4) , 307-313
Open AccessOff-Label Use of Dalbavancin in Enterococcus spp. Abscess and Streptococcus pneumoniae Bacteremia Secondary to Septic Arthritis: A Retrospective Case Report
Dalbavancin, a semi-synthetic lipoglycopeptide with an extended half-life that allows for weekly dosing, is currently approved for the treatment of bacterial skin and soft tissue infections caused by susceptible gram-positive organisms. This case report discusses the successful treatment of septic arthritis with dalbavancin in a 38-year-old obese male. Septic arthritis, commonly caused by Staphylococcus aureus and Streptococcus species, was diagnosed in this patient following a mechanical fall that led to worsening shoulder pain. Given the patient’s morbid obesity and concerns about antibiotic penetration, dalbavancin 1500 mg IV biweekly was chosen for its extended half-life and ease of administration. This case underscores dalbavancin’s efficacy in managing septic arthritis in obese patients, offering a convenient alternative to traditional therapies that require a peripherally inserted central catheter (PICC line), frequent dosing, therapeutic monitoring, and prolonged hospital stays. Despite its higher cost, dalbavancin’s advantages include reduced need for PICC lines, additional staff and resources to monitor therapeutic drug levels, and fewer complications, which can offset some expenses. To our knowledge, this is the first documented case investigating the use of dalbavancin for enterococcal septic arthritis with a biweekly dosing regimen.
- 6 May 2021
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 16 (8) , 2231-2241
Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections
Antimicrobial resistance is a growing threat to public health and an increasingly common problem for acute care physicians to confront. Several novel antibiotics have been approved in the past decade to combat these infections; however, physicians may be unfamiliar with how to appropriately utilize them. The purpose of this review is to evaluate novel antibiotics active against resistant gram-negative bacteria and highlight clinical information regarding their use in the acute care setting. This review focuses on novel antibiotics useful in the treatment of infections caused by resistant gram-negative organisms that may be seen in the acute care setting. These novel antibiotics include ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilistatin/relebactam, cefiderocol, plazomicin, eravacycline, and omadacycline. Acute care physicians should be familiar with these novel antibiotics so they can utilize them appropriately.
- 6 May 2021
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 16 (8) , 2231-2241
Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections
Antimicrobial resistance is a growing threat to public health and an increasingly common problem for acute care physicians to confront. Several novel antibiotics have been approved in the past decade to combat these infections; however, physicians may be unfamiliar with how to appropriately utilize them. The purpose of this review is to evaluate novel antibiotics active against resistant gram-negative bacteria and highlight clinical information regarding their use in the acute care setting. This review focuses on novel antibiotics useful in the treatment of infections caused by resistant gram-negative organisms that may be seen in the acute care setting. These novel antibiotics include ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilistatin/relebactam, cefiderocol, plazomicin, eravacycline, and omadacycline. Acute care physicians should be familiar with these novel antibiotics so they can utilize them appropriately.